Human Immunology News Volume 10.09 | Mar 8 2022

    0
    94







    2022-03-08 | HIN 10.09


    Human Immunology News by STEMCELL Technologies
    Vol. 10.09 – 8 March, 2022
    TOP STORY

    KIR+CD8+ T Cells Suppress Pathogenic T Cells and Are Active in Autoimmune Diseases and COVID-19

    CD8+ T expressing inhibitory killer cell immunoglobulin-like receptors cells efficiently eliminated pathogenic gliadin-specific CD4+ T cells from celiac disease patients’ leukocytes in vitro.
    [Science]

    Full ArticlePress Release
    Subscribe to the Immunology Podcast YouTube Channel
    PUBLICATIONSRanked by the impact factor of the journal

    Characterization of INCB086550, a Potent and Novel Small-Molecule PD-L1 Inhibitor

    Scientists described the identification and characterization of INCB086550, a novel, oral, small-molecule programmed cell death protein 1 (PD-L1) inhibitor.
    [Cancer Discovery]

    Abstract

    Tertiary Lymphoid Structures Generate and Propagate Anti-Tumor Antibody-Producing Plasma Cells in Renal Cell Cancer

    Researchers used spatial transcriptomics to examine the nature of B cell responses within tertiary lymphoid structures in renal cell carcinoma.
    [Immunity]

    AbstractGraphical Abstract

    TET2 Inactivation Restrains IL-10-Producing Regulatory B Cells to Enable Anti-Tumor Immunity in Hepatocellular Carcinoma

    TET2 activation in B cells triggered by oxidative stress from the hepatocellular carcinoma (HCC) microenvironment promoted IL-10 expression, while the adoptive transfer of Tet2-deficient B cells suppressed HCC progression.
    [Hepatology]

    Abstract

    Single-Cell Profiling of Human CD127+ Innate Lymphoid Cells Reveals Diverse Immune Phenotypes in Hepatocellular Carcinoma

    Investigators applied selection strategies to enrich innate lymphoid cells (ILC) populations in hepatocellular carcinoma samples to investigate the effects of B cells on the immune reaction of ICOS+ ILC2 cells.
    [Hepatology]

    AbstractFull Article

    Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab, in Patients with Advanced Non-Small Cell Lung Cancer

    In a Phase I/Ib, dose-escalation/expansion study, patients with advanced/metastatic non-small cell lung cancer and 1 prior therapy received taminadenant with or without spartalizumab.
    [Clinical Cancer Research]

    Abstract

    Tumor-B Cell Interactions Promote Isotype Switching to an Immunosuppressive IgG4 Antibody Response through Upregulation of IL-10 in Triple Negative Breast Cancers

    Investigators performed co-culture assays to examine expression of Th2 cytokines by triple negative breast cancer cells with and without the presence of B cells.
    [Journal of Translational Medicine]

    Full Article

    S1P Analogues SEW2871, BAF312 and FTY720 Affect Human Th17 and Treg Generation Ex Vivo

    The authors investigated the effects of S1P receptor 1 (S1P1) specific S1P analogue SEW2871, S1P1 and S1P5 specific Siponimod (BAF312), and non-selective (fingolimod) FTY720 on human Th17 and Treg differentiation and IL-23-mediated signaling.
    [International Immunopharmacology]

    AbstractFull Article

    The Interaction of CD4+ Helper T Cells with Dendritic Cells Shapes the Tumor Microenvironment and Immune Checkpoint Blockade Response

    Researchers systematically characterized the interactions between T cells and antigen-presenting myeloid cells within the tumor microenvironment and found that CD4+PD-1+CXCL13+ T cells were a major interacting hub with antigen-presenting cells in the tumor microenvironment of human non-small cell lung carcinoma.
    [Nature Cancer]

    AbstractPress Release

    How can evaluating the immuno-oncology potential of compounds in vitro predict clinical outcomes? Watch this webinar by Dr. Alison O'Mahony, Eurofins DiscoverX
    REVIEWS

    Dendritic Cells a Critical Link to Alveolar Bone Loss and Systemic Disease Risk in Periodontitis: Immunotherapeutic Implications

    Dendritic cells consist of multiple subsets that reside in the epithelium, connective tissues, and major organs.
    [Periodontology 2000]

    Abstract

    The Importance of miRNA-630 in Human Diseases with an Especial Focus on Cancers

    Expression levels of miR-630 can be used as markers for prediction of cancer course. Moreover, miR-630 can influence response to chemoradiotherapy.
    [Cancer Cell International]

    Full Article
    INDUSTRY AND POLICY NEWS

    Women’s Brain Health Initiative and Brain Canada Join Forces to Fund Sex and Gender Considerations in Brain Research

    Six Canadian research teams have been awarded funding for the implementation and/or continuation of sex and gender considerations in research on aging, neurodegeneration, and stroke.
    [Brain Canada Foundation]

    Press Release

    BioNTech and Regeneron Expand Strategic Collaboration to Advance Clinical Development of FixVac and Libtayo® (Cemiplimab) Combination in NSCLC

    BioNTech SE announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo®, a PD-1 inhibitor, in advanced non-small cell lung cancer.
    [BioNTech SE]

    Press Release
    FEATURED EVENT

    EMBO: Microbial Infections and Human Cancer

    April 6 – 9, 2022
    Heidelberg, Germany

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Scientist – Liver Resident Memory T Cell

    Amsterdam UMC – Amsterdam, Netherlands

    Research Scientist – CAR T Cells

    BioNTech – Gaithersburg, Maryland, United States

    Postdoctoral Positions – Human Immunology and Inflammation

    National Institute for Health and Medical Research – Paris, France

    Postdoctoral Associate – Cell Viability

    Singapore-MIT Alliance for Research and Technology (SMART) Centre – Singapore, Singapore

    Postdoctoral Position – Tissue Engineering and Epigenetics

    University of Lausanne – Lausanne, Switzerland

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter